乾癬の世界市場レポート 2024年

乾癬の市場規模は近年急速に拡大しています。2023年の238億7,000万米ドルから2024年には265億米ドルへと、CAGR11.0％で拡大します。過去の期間に見られた成長は、疫学の進歩、乾癬に関する患者の意識と教育の向上、医療インフラの改善と治療を求める人々へのアクセスなど、さまざまな要因によるものです。

乾癬治療に関連する高コストは、予測期間中の市場成長の抑制要因として作用すると予想されます。例えば、WebMDの報告によると、乾癬性関節炎（PsA）治療のための疾患修飾性抗リウマチ薬（DMARD）の使用には、年間1,500ドルから2,000ドルの費用がかかります。米国では、皮膚科医の診察料は通常150ドルから200ドルです。特許保護により、より手頃な代替薬へのアクセスが制限されることが多く、乾癬治療の高額な費用の一因となり、その後の市場成長の妨げとなっています。

乾癬治療薬の承認プロセスは、近年乾癬治療薬の承認が増加していることからもわかるように、世界規模でより合理的になってきています。代表的な例としては、日本におけるプラーク乾癬治療薬SKYRIZI（リサンキズマブ）の承認や、Center for Drug Evaluation and Researchによるプラーク乾癬治療薬Avsola（インフリキシマブ-axxq）の承認が挙げられます。このような医薬品承認プロセスの簡素化は、予測期間において乾癬市場を牽引すると予想されます。

2023年の乾癬市場では北米が最大地域でした。中東は予測期間中、乾癬市場で最も急成長する地域と予想されます。乾癬市場レポートの対象地域は、アジア太平洋、西欧、東欧、北米、南米、中東・アフリカです。

目次

第1章 エグゼクティブサマリー

第2章 乾癬市場の特徴

第3章 乾癬市場の動向と戦略

第4章 乾癬市場-マクロ経済シナリオ

第5章 世界の乾癬市場規模と成長

• 世界の乾癬市場の促進要因と抑制要因
  • 市場の促進要因
  • 市場の抑制要因
• 世界の乾癬の市場規模実績と成長率、2018～2023年
• 世界の乾癬市場規模と成長予測、2023～2028年、2033年

第6章 乾癬市場セグメンテーション

• 世界の乾癬市場、薬剤のタイプ別セグメンテーション、実績と予測、2018～2023年、2023～2028年、2033年
• 低分子
• 生物製剤
• 世界の乾癬市場、薬剤クラス別セグメンテーション、実績と予測、2018～2023年、2023～2028年、2033年
• インターロイキン阻害剤
• コルチコステロイド
• 抗炎症
• 腫瘍壊死因子阻害剤
• 世界の乾癬市場、疾患適応別セグメンテーション、実績と予測、2018～2023年、2023～2028年、2033年
• 尋常性乾癬
• 爪乾癬
• 滴状乾癬
• 膿疱性乾癬
• 赤皮症乾癬
• 世界の乾癬市場、投与経路別セグメンテーション、実績と予測、2018～2023年、2023～2028年、2033年
• 経口
• 局所
• 注射
• 世界の乾癬市場、流通チャネル別セグメンテーション、実績と予測、2018～2023年、2023～2028年、2033年
• 病院
• 小売薬局
• eコマース

第7章 乾癬市場の地域と国分析

• 世界の乾癬市場、地域別、実績と予測、2018～2023年、2023～2028年、2033年
• 世界の乾癬市場、国別、実績と予測、2018～2023年、2023～2028年、2033年

第8章 アジア太平洋の乾癬市場

第9章 中国の乾癬市場

第10章 インドの乾癬市場

第11章 日本の乾癬市場

第12章 オーストラリアの乾癬市場

第13章 インドネシアの乾癬市場

第14章 韓国の乾癬市場

第15章 西欧の乾癬市場

第16章 英国の乾癬市場

第17章 ドイツの乾癬市場

第18章 フランスの乾癬市場

第19章 イタリアの乾癬市場

第20章 スペインの乾癬市場

第21章 東欧の乾癬市場

第22章 ロシアの乾癬市場

第23章 北米の乾癬市場

第24章 米国の乾癬市場

第25章 カナダの乾癬市場

第26章 南米の乾癬市場

第27章 ブラジルの乾癬市場

第28章 中東の乾癬市場

第29章 アフリカの乾癬市場

第30章 乾癬市場の競合情勢と企業プロファイル

• 乾癬市場の競合情勢
• 乾癬市場の企業プロファイル
  • AbbVie Inc.
  • Pfizer Inc.
  • Novartis AG
  • Eli Lilly and Company
  • Celgene Corporation

第31章 世界の乾癬市場の競合ベンチマーキング

第32章 世界の乾癬市場の競合ダッシュボード

第33章 乾癬市場における主要な合併と買収

第34章 乾癬市場の将来展望と可能性分析

第35章 付録

“Psoriasis Global Market Report 2024 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on psoriasis market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for psoriasis? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The psoriasis market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

• 1) By Drug class: Interleukin Inhibitors; Corticosteroids; Anti-Inflammatory; Tumor Necrosis Factor Inhibitor
• 2) By Drug Types: Small molecules; Biologics
• 3) By Disease Indication: Plaque Psoriasis; Nail Psoriasis; Guttate Psoriasis; Pustular Psoriasis; Erythrodermic Psoriasis
• 4) By Route Of Administration: Oral; Tropical; Injectable
• 5) By Distribution Channel: Hospitals; Retail Pharmacies; E-Commerce
• Companies Mentioned: AbbVie Inc.; Pfizer Inc.; Novartis AG; Eli Lilly and Company; Celgene Corporation
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Psoriasis is a skin condition characterized by the development of a rash with itchy, scaly patches, typically affecting areas such as the knees, elbows, trunk, and scalp. The underlying cause is often related to an immune system dysfunction where infection-fighting cells mistakenly attack healthy skin cells.

The primary categories of drugs used to manage psoriasis include interleukin inhibitors, corticosteroids, anti-inflammatories, and tumor necrosis factor inhibitors. Corticosteroids are a group of steroid hormones produced by the adrenal cortex in vertebrates and can also be synthesized as medications. These drugs come in various forms, including small molecules and biologics, and are applied to treat different manifestations of the disease, such as plaque psoriasis, nail psoriasis, guttate psoriasis, pustular psoriasis, and erythrodermic psoriasis. They are administered via various routes, including oral, topical, and injectable methods and can be obtained through hospitals, retail pharmacies, and e-commerce channels.

The psoriasis market research report is one of a series of new reports from The Business Research Company that provides psoriasis market statistics, including psoriasis industry global market size, regional shares, competitors with a psoriasis market share, detailed psoriasis market segments, market trends, and opportunities, and any further data you may need to thrive in the psoriasis industry. This psoriasis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The psoriasis market size has grown rapidly in recent years. It will grow from $23.87 billion in 2023 to $26.5 billion in 2024 at a compound annual growth rate (CAGR) of 11.0%. The growth observed during the historical period can be attributed to various factors, including advances in epidemiology, increased patient awareness and education regarding psoriasis, and improvements in healthcare infrastructure and access for those seeking treatment.

The psoriasis market size is expected to see rapid growth in the next few years. It will grow to $39.17 billion in 2028 at a compound annual growth rate (CAGR) of 10.3%. The projected growth in the forecast period can be attributed to factors such as regulatory approvals for new treatments, evolving patient preferences, a growing aging population, increased awareness of psoriasis, and the introduction of innovative therapies. Prominent trends in this forecast period encompass advancements in research and development, the rise of biologics and targeted therapies, the emergence of oral small molecule therapies, the adoption of personalized medicine, the integration of telemedicine and digital health solutions, the promotion of patient-centric care models, the utilization of biosimilars, and the incorporation of artificial intelligence and machine learning in healthcare for psoriasis management.

The increasing prevalence of psoriasis patients is a driving force behind the growth of the psoriasis market. Psoriasis, a skin condition, is influenced by factors such as the immune system, genetics, and environmental factors. Over recent years, the surge in psoriasis cases can be primarily attributed to climate changes, elevated stress levels, and unhealthy lifestyles. The World Psoriasis Day consortium reports that a significant 2 to 3% of the global population, which translates to 125 million individuals, suffers from psoriasis. Consequently, the escalating number of psoriasis patients is expected to be a key driver for the growth of the psoriasis market in the foreseeable future.

The psoriasis market is poised for growth, thanks to the increasing geriatric population. This demographic, composed of individuals aged 65 years and older, is more prone to conditions like hypertension, diabetes, and elevated blood glucose levels, which can exacerbate psoriasis. According to the World Health Organization's October 2022 data, one in six individuals worldwide will be 60 or older by 2030, with the total population in this age group expected to reach 1.4 billion, up from 1 billion in 2020. The number of people aged 80 or older is predicted to triple to 426 million by 2050. Consequently, the rising geriatric population is a driving force behind the growth of the psoriasis market.

The high cost associated with psoriasis therapy is expected to act as a constraint on the market's growth over the forecast period. For instance, reported by WebMD, the use of disease-modifying antirheumatic medications (DMARD) for treating Psoriatic Arthritis (PsA) can cost between $1,500 and $2,000 annually. In the United States, a dermatologist office visit typically ranges from $150 to $200. Patent protections often limit access to more affordable alternative medications, contributing to the high cost of psoriasis therapy and subsequently hampering market growth.

An emerging trend in the psoriasis market is the use of combination therapy. Combination therapy involves the simultaneous use of two different psoriasis treatments. Combining drugs with distinct mechanisms of action (combination therapy) often results in more significant treatment effects compared to monotherapy (using a single drug). Studies indicate that combination therapy provides more effective relief from psoriasis symptoms and is associated with fewer side effects. An example of combination therapy for treating active Psoriatic Arthritis (PsA) is the combination of Taltz (ixekizumab) with methotrexate, a development by Eli Lilly and Company.

Major companies operating in the psoriasis market are intensifying their efforts to introduce innovative products and secure approval from regulatory agencies, aiming to maximize their market revenues. The drug development and approval process is intricate and time-consuming, requiring drug sponsors to navigate the regulatory framework and marketing pathways to ensure safety and effectiveness. As an illustration, in September 2022, Boehringer Ingelheim, a Germany-based pharmaceutical company, received approval from the U.S. Food and Drug Administration (FDA) for SPEVIGO, marking the first approved treatment for generalized pustular psoriasis (GPP) flare-ups in adults. SPEVIGO is a novel, highly selective antibody designed to inhibit the interleukin-36 receptor (IL-36R) activation, a pivotal component of an immune system signaling pathway linked to GPP development. GPP, characterized by periods of widespread eruptions of sterile pustules, is a rare and potentially life-threatening neutrophilic skin condition.

The process of approving psoriasis drugs has become more streamlined on a global scale, as evidenced by the increasing approvals of drugs for psoriasis in recent years. Some notable examples include the regulatory approval of SKYRIZI (risankizumab) for plaque psoriasis treatment in Japan and the Center for Drug Evaluation and Research's approval of Avsola (infliximab-axxq) for treating plaque psoriasis. This simplified drug approval process is expected to drive the psoriasis drugs market in the forecast period.

Major companies operating in the psoriasis market include AbbVie Inc., Pfizer Inc., Novartis AG, Eli Lilly and Company, Celgene Corporation, Johnson & Johnson, Amgen Inc., Boehringer Ingelheim GmbH, Merck & Co. Inc., Janssen Biotech Inc., Takeda Pharmaceutical Company Limited, Stiefel Laboratories Inc., AstraZeneca Inc., Union Chimique Belge SA, Sun Pharmaceutical Industries Ltd., Forward Pharma AS, Almirall SA, Bausch Health Companies Inc., Biogen Inc., Biocon Biopharmaceuticals Pvt. Ltd., Celltrion Inc., Dr.Reddy's Laboratories Inc., Arcutis Biotherapeutics Inc., Bayer AG, Bristol Myers Squibb Co., Dermira Inc., Galderma SA, GlaxoSmithKline PLC, Incyte Pharmaceuticals Corp., LEO Pharmacy

North America was the largest region in the psoriasis market in 2023. Middle East is expected to be the fastest-growing region in the psoriasis market during the forecast period. The regions covered in the psoriasis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the psoriasis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada

The psoriasis market consists of sales of Methotrexate, Ciclosporin, and Acitretin. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Table of Contents

1. Executive Summary

2. Psoriasis Market Characteristics

3. Psoriasis Market Trends And Strategies

4. Psoriasis Market - Macro Economic Scenario

• 4.1. Impact Of High Inflation On The Market
• 4.2. Ukraine-Russia War Impact On The Market
• 4.3. COVID-19 Impact On The Market

5. Global Psoriasis Market Size and Growth

• 5.1. Global Psoriasis Market Drivers and Restraints
  • 5.1.1. Drivers Of The Market
  • 5.1.2. Restraints Of The Market
• 5.2. Global Psoriasis Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
• 5.3. Global Psoriasis Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Psoriasis Market Segmentation

• 6.1. Global Psoriasis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Small molecules
• Biologics
• 6.2. Global Psoriasis Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Interleukin Inhibitors
• Corticosteroids
• Anti-Inflammatory
• Tumor Necrosis Factor Inhibitor
• 6.3. Global Psoriasis Market, Segmentation By Disease Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Plaque Psoriasis
• Nail Psoriasis
• Guttate Psoriasis
• Pustular Psoriasis
• Erythrodermic Psoriasis
• 6.4. Global Psoriasis Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Oral
• Tropical
• Injectable
• 6.5. Global Psoriasis Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Hospitals
• Retail Pharmacies
• E-Commerce

7. Psoriasis Market Regional And Country Analysis

• 7.1. Global Psoriasis Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 7.2. Global Psoriasis Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Psoriasis Market

• 8.1. Asia-Pacific Psoriasis Market Overview
• Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Psoriasis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.3. Asia-Pacific Psoriasis Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.4. Asia-Pacific Psoriasis Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Psoriasis Market

• 9.1. China Psoriasis Market Overview
• 9.2. China Psoriasis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.3. China Psoriasis Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.4. China Psoriasis Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Psoriasis Market

• 10.1. India Psoriasis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.2. India Psoriasis Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.3. India Psoriasis Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Psoriasis Market

• 11.1. Japan Psoriasis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.2. Japan Psoriasis Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.3. Japan Psoriasis Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Psoriasis Market

• 12.1. Australia Psoriasis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.2. Australia Psoriasis Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.3. Australia Psoriasis Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Psoriasis Market

• 13.1. Indonesia Psoriasis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.2. Indonesia Psoriasis Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.3. Indonesia Psoriasis Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Psoriasis Market

• 14.1. South Korea Psoriasis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.2. South Korea Psoriasis Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.3. South Korea Psoriasis Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Psoriasis Market

• 15.1. Western Europe Psoriasis Market Overview
• 15.2. Western Europe Psoriasis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.3. Western Europe Psoriasis Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.4. Western Europe Psoriasis Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Psoriasis Market

• 16.1. UK Psoriasis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.2. UK Psoriasis Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.3. UK Psoriasis Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Psoriasis Market

• 17.1. Germany Psoriasis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.2. Germany Psoriasis Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.3. Germany Psoriasis Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Psoriasis Market

• 18.5. France Psoriasis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.6. France Psoriasis Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.7. France Psoriasis Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Psoriasis Market

• 19.9. Italy Psoriasis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.10. Italy Psoriasis Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.11. Italy Psoriasis Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Psoriasis Market

• 20.13. Spain Psoriasis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.14. Spain Psoriasis Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.15. Spain Psoriasis Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Psoriasis Market

• 21.1. Eastern Europe Psoriasis Market Overview
• 21.2. Eastern Europe Psoriasis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.3. Eastern Europe Psoriasis Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.4. Eastern Europe Psoriasis Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Psoriasis Market

• 22.1. Russia Psoriasis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.2. Russia Psoriasis Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.3. Russia Psoriasis Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Psoriasis Market

• 23.1. North America Psoriasis Market Overview
• 23.2. North America Psoriasis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.3. North America Psoriasis Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.4. North America Psoriasis Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Psoriasis Market

• 24.1. USA Psoriasis Market Overview
• 24.2. USA Psoriasis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.3. USA Psoriasis Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.4. USA Psoriasis Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Psoriasis Market

• 25.1. Canada Psoriasis Market Overview
• 25.2. Canada Psoriasis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.3. Canada Psoriasis Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.4. Canada Psoriasis Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Psoriasis Market

• 26.1. South America Psoriasis Market Overview
• 26.2. South America Psoriasis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.3. South America Psoriasis Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.4. South America Psoriasis Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Psoriasis Market

• 27.1. Brazil Psoriasis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.2. Brazil Psoriasis Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.3. Brazil Psoriasis Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Psoriasis Market

• 28.1. Middle East Psoriasis Market Overview
• 28.2. Middle East Psoriasis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.3. Middle East Psoriasis Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.4. Middle East Psoriasis Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Psoriasis Market

• 29.1. Africa Psoriasis Market Overview
• 29.2. Africa Psoriasis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.3. Africa Psoriasis Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.4. Africa Psoriasis Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Psoriasis Market Competitive Landscape And Company Profiles

• 30.1. Psoriasis Market Competitive Landscape
• 30.2. Psoriasis Market Company Profiles
  • 30.2.1. AbbVie Inc.
    • 30.2.1.1. Overview
    • 30.2.1.2. Products and Services
    • 30.2.1.3. Strategy
    • 30.2.1.4. Financial Performance
  • 30.2.2. Pfizer Inc.
    • 30.2.2.1. Overview
    • 30.2.2.2. Products and Services
    • 30.2.2.3. Strategy
    • 30.2.2.4. Financial Performance
  • 30.2.3. Novartis AG
    • 30.2.3.1. Overview
    • 30.2.3.2. Products and Services
    • 30.2.3.3. Strategy
    • 30.2.3.4. Financial Performance
  • 30.2.4. Eli Lilly and Company
    • 30.2.4.1. Overview
    • 30.2.4.2. Products and Services
    • 30.2.4.3. Strategy
    • 30.2.4.4. Financial Performance
  • 30.2.5. Celgene Corporation
    • 30.2.5.1. Overview
    • 30.2.5.2. Products and Services
    • 30.2.5.3. Strategy
    • 30.2.5.4. Financial Performance

31. Global Psoriasis Market Competitive Benchmarking

32. Global Psoriasis Market Competitive Dashboard

33. Key Mergers And Acquisitions In The Psoriasis Market

34. Psoriasis Market Future Outlook and Potential Analysis

• 34.1 Psoriasis Market In 2028 - Countries Offering Most New Opportunities
• 34.2 Psoriasis Market In 2028 - Segments Offering Most New Opportunities
• 34.3 Psoriasis Market In 2028 - Growth Strategies
• 34.3.1 Market Trend Based Strategies
• 34.3.2 Competitor Strategies

35. Appendix

• 35.1. Abbreviations
• 35.2. Currencies
• 35.3. Historic And Forecast Inflation Rates
• 35.4. Research Inquiries
• 35.5. The Business Research Company
• 35.6. Copyright And Disclaimer